CPI-003

CPI-003 is Capricor’s core autologous stem cell program for the treatment of myocardial infarct or MI. The autologous Cardiac Derived Cells or CDC Program has achieved proof of concept in the laboratory and a variety of small and large animal models. A pivotal IND enabling large animal study was completed in September 2007. An Investigational New Drug (IND) application is under preparation and will be submitted to the Food & Drug Administration (FDA) in collaboration with groups from Cedars-Sinai Medical Center, Johns Hopkins Medical School, and the University of Minnesota 's Molecular and Cellular Therapeutics facility.

CPI-004

CPI-004 builds upon the successful preparation of CDC cells for treatment of myocardial infarct. One of the key issues for any cardiac stem cell therapy is the method of delivery of the cells into the heart, in a manner allowing the cells to remain viable, functional, and able to repair the heart muscle. While direct infusion into the cardiac veins and heart muscle have had success, various matrices have been shown to benefit survival and function of stem cells. Capricor is engaged in studies to develop and optimize CDC and matrix combinations to dramatically increase the therapeutic effectiveness of cardiac stem cell treatment in collaboration with matrix and tissue engineering partners.